Biotech shares soar on research, marketing progress


It's taken more than 15 years and $120 million of investor money, but the starting line is in sight for biotech Clinuvel Pharmaceutical, which has signalled it is moving closer to product launch. That news resulted in its share price surging on Wednesday, along with the shares of Reva Medical, which disclosed further research results that also fired up investor optimism.



from Biotech News